Advertisement

Pharmaceutisch Weekblad

, Volume 11, Issue 1, pp 3–8 | Cite as

Pharmacochemical aspects of leprosy

Recent developments and prospects for new drugs
  • P. van Saane
  • H. Timmerman
Update Articles

Abstract

From a pharmacochemical point of view the existing anti-leprotics as well as possible innovations in the chemotherapy of leprosy are discussed. Of the main anti-leprotics, which are used nowadays — dapsone, rifampicin, clofazimine, isoniazide, ethionamide and prothionamide — the mechanism of action, the main problems in their application and possibilities to develop improved variants are reviewed. Based on the chemistry ofMycobacterium leprae, the target systems for new anti-leprotics are identified. These systems include the cell wall, the catabolism of reactive oxygen species, the metabolisms of carbon sources, the amino acid metabolism and the uptake of iron. Two possible new lead structures from other fields, 4-quinolones and mycobacterial ribonucleotide reductase inhibitors are presented.

Keywords

Biochemistry Clofazimine Dapsone Ethionamide Isoniazide Mechanism of action Mycobacterium leprae Prothionamide Quinolones Ribonucleotide reductase inhibitors Rifampicin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anonymous. Vaccination trials against leprosy. A meeting of the epidemiology subgroup of the scientific working group on the immunology of leprosy. WHO/TDR/IMMLEP/EPD/85.3, 1985.Google Scholar
  2. 2.
    Seydel JK, Wempe EG. Bacterial growth kinetics ofM. lufu, in the presence and absence of various drugs alone and in combination. A model for the development of combined chemotherapy againstM. leprae. Int J Lepr 1982;50(1):20–31.Google Scholar
  3. 3.
    Acocella G. Rifampicin: a brief outline of its microbiological, pharmacokinetic and clinical features. Quad Cooperazione Sanitaria 1981;1:21–3.Google Scholar
  4. 4.
    Leiker DL. Clofazimine in the treatment of leprosy. Quad Cooperazione Sanitaria 1982;1:155–8.Google Scholar
  5. 5.
    Shepard CC, Van Landingham RM, Walker LL. Recent studies of antileprosy drugs. Lepr Rev 1983;54:235–305.Google Scholar
  6. 6.
    Cabot MC. Chaulmoogric acid. Assimilation into the complex lipids of mycobacteria. Lipids 1981;16(2):146–8.PubMedGoogle Scholar
  7. 7.
    Chaudhuri S, Glosh S, Chakraborty T, Kundu S, Hazra SK. Use of a common Indian herb Mandukarpani in the treatment of leprosy. Lepr India 1979;51(1):106–11.PubMedGoogle Scholar
  8. 8.
    Kulkarni VM, Seydel JK. Inhibitory activity and mode of action of DDS in cell free folate synthesizing system fromM. lufu andM. leprae. Chemotherapy 1983;29:58–67.PubMedGoogle Scholar
  9. 9.
    Seydel JK, Wempe EG, Rosenfeld M. Bacterial growth kinetics ofE. coli and mycobacteria in the presence of bromoprim and metioprim alone and in combination with aulfamemazine and dapsone. IV. Chemotherapy 1983;29:249–62.PubMedGoogle Scholar
  10. 10.
    Ungheri D, Bruna DC, Sanfilipo A. Studies on the mechanism of action of the spiropiperidyl rifampicin LM.427 on rifampicin-resistantM. tuberculosis. Drugs Exp Clin Res 1984;10:681–9.Google Scholar
  11. 11.
    Arioli V, Berti M, Garniti G. Antibacterial activity of DL.473, a new semi-synthetic rifamycin derivative. J Antiobiot (Tokyo) 1981;34(8):1026–32.Google Scholar
  12. 12.
    Zierksi M, Rotermund C. Isoniazid: essential facts and new information. Prax Klin Pneumol 1984;38:65–73.Google Scholar
  13. 13.
    Draper P. Wall biosynthesis: a possible site of action for new anti-mycobacterial drugs. Int J Lepr 1984;52(4):527–32.Google Scholar
  14. 14.
    Wheeler PR. Metabolism inM. leprae. Its relation to other research onM. leprae and to aspects of metabolism in other mycobacteria and intracellular parasites [Editorial]. Int J Lepr 1984;52(2):208–30.Google Scholar
  15. 15.
    Jayamaran P, Mahadevan P, Mester L, Mester M. Inhibition of the incorporation of3H-DOPA inM. leprae by DFS. Biochem Pharm 1980;29:2526–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Ferraci C, Baquillon G, Pattyn SR. Action of DFS onM. leprae. Results of inoculation of mice with human biopsies taken after 1 year of treatment. Acta Leprol 1983;93:233–5.Google Scholar
  17. 17.
    Mester L, Rees RJW, Ambrose ES, Mester M. A series of new anti-leprosy compounds derived from serotonin. Acta Leprol Logica 1985:21–8.Google Scholar
  18. 18.
    Kato L. Absence of micobactin inM. leprae. Probably a microbe-dependent micro-organism: implications. Indian J Lepr 1985;57(1):58–70.PubMedGoogle Scholar
  19. 19.
    Guelpa-Lanras C, Perani EG, Giroir A, Grosset JH. Activitities of pefloxacin and ciprofloxacin againstM. leprae in the mouse. Int J Lepr 1987;55(1):70–7.Google Scholar
  20. 20.
    Saito H, Tomioka H, Nagashima K.In vitro andin vivo activities of ofloxacin againstM. leprae infection induced in mouse. Int J Lepr 1986;54(4):560–2.Google Scholar
  21. 21.
    Schaper K-J, Seydel JK, Rosenfeld M, Kazda J. Development of inhibitors of mycobacterial ribonucleotide reductase. Lepr Rev 1986;57:254–64.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1989

Authors and Affiliations

  • P. van Saane
    • 1
  • H. Timmerman
    • 1
  1. 1.Division of PharmacochemistryFree UniversityHV AmsterdamThe Netherlands

Personalised recommendations